PIM
LKFT

Provident Investment Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Provident Investment Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,700
Closed -$249K – 59
2018
Q2 		$249K Buy
+2,700
New +$262K 0.04% 55

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Provident Investment Management's LKFT Position: Q3 2018 in Review

Provident Investment Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2018, closing a stake of 2,700 shares — an estimated $249K sold.

Provident Investment Management first reported a position in LKFT in Q2 2018 and held it in 1 quarter. The position peaked at $249K in Q2 2018. 92 funds tracked by Wall St. Rank hold LKFT as of Q3 2018.

  • Provident Investment Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2018 after selling out during the quarter.
  • Provident Investment Management sold 2,700 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2018, an estimated $249K.
  • Provident Investment Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2018 and held it in 1 quarter.
  • Provident Investment Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $249K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2018.

Based on Provident Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.